REPH - Recro Pharma, Inc.

Recro Pharma, Inc (REPH) is a specialty pharmaceutical company that develops and commercializes innovative products and therapies for hospital and related acute care settings. The company has a focus on acute care pain management, which includes hospital-based therapies, non-opioid analgesics, and innovative drug delivery systems.

Recro Pharma has developed an innovative drug delivery system called the Acuform drug delivery technology. This technology allows for controlled and extended release of active pharmaceutical ingredients (APIs) that are often difficult to deliver through traditional methods. The Acuform technology is used in the company's lead product, IV meloxicam, which is a non-opioid pain medication that is used for the management of moderate to severe pain.

In addition to IV meloxicam, Recro Pharma has a number of other products in development, including a non-opioid analgesic for post-operative pain, and a treatment for acute migraine headaches. The company also has a number of partnerships with other pharmaceutical companies for the development of novel products and technologies.

Recro Pharma was founded in 2007 and is headquartered in Malvern, Pennsylvania. The company's stock is traded on the NASDAQ exchange under the ticker symbol REPH.